Clinical trials: Invasive Fungal Infection
Fungal Infection, Critical Illness
Fungal Biomarkers to Reduce Duration of Empirical Antifungal Therapy: a Randomized Comparative Study (STAFE)
The investigators hypothesized that the use of biomarkers of invasive fungal infections would increase the percentage of early discontinuation of empirical antifungal therapy and thus reduce the duration of treatment in ICU…
- Trial name
- STAFE (NCT02154178)
- Testing
- Biomarker group
- Where
- France
- Volunteers
- 110 people
- Sponsor
- University Hospital, Lille
Invasive Fungal Infections
Study on the Pharmacokinetic Characteristics of Liposomal Amphotericin B in Patients With Invasive Fungal Infections Undergoing Plasma Exchange Therapy
The goal of this prospective study is to describe the pharmacokinetic characteristics of liposomal amphotericin B during plasma exchange therapy for severe invasive fungal infections in Chinese patients, preliminarily explore the…
- Trial name
- NCT07532850
- Testing
- Collection of pharmacokinetic samples to explore the pharmacokinetic characteristics in severe invasive fungal infection patients receive liposomal amphotericin B who undergo plasma exchange therapy.
- Volunteers
- 10 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Candidemia, Mycoses
Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
The purpose of this pivotal study is to determine if intravenous Rezafungin is efficacious and safe in the prevention of invasive fungal diseases when compared to the standard antimicrobial regimen.
- Conditions
- Candidemia, Mycoses, Fungal Infection, Fungemia
- Trial name
- ReSPECT (NCT04368559)
- Testing
- Rezafungin for Injection, Posaconazole, Fluconazole
- Where
- 53 sites in United States, Belgium and 7 more
- Volunteers
- 602 people
- Sponsor
- Mundipharma Research Limited
Liver Cirrhosis, Viral Pneumonia
Liver Cirrhosis Patients With Invasive Pulmonary Aspergillosis: in Depth Understanding Clinical Host Risk Factors
Invasive pulmonary aspergillosis (IPA) is a life-threatening fungal infection of the respiratory system, caused by a specific fungus called Aspergillus species.
- Conditions
- Liver Cirrhosis, Viral Pneumonia, Fungal Infection, Invasive Pulmonary Aspergillosis
- Trial name
- LIVERIPA (NCT07238114)
- Where
- Belgium
- Volunteers
- 450 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Fungal Disease
A Real-world Prospective Observational Study on the Efficacy and Safety of L-AmB(Liposomal Amphotericin B) for br- IFD(Breakthrough Invasive Fungal Disease) in Children and Adolescent Patients With Hematological Malignancies Receiving Triazoles or Echinocandins Prophylaxis
The goal of this observational study is to evaluate the efficacy the favorable response rate and safety of L-AmB(liposomal amphotericin B) for the treatment of br-IFD(breakthrough invasive fungal disease) in Chinese children and…
- Trial name
- NCT07357038
- Testing
- Patients received the Drug: liposomal amphotericin B（AmBisome） for treatment
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Invasive Fungal Disease, Critical Illness
De-escalation - Antifungal Treatment Immunocompromised Patients
A small proportion of intensive care unit patients receiving antifungals have a proven invasive fungal infection. However, antifungal treatment has side effects such as toxicity, emergence of resistance, and high cost.
- Trial name
- D-ATFIM (NCT03774316)
- Where
- France
- Volunteers
- 275 people
- Sponsor
- University Hospital, Lille
Enterobacterial Infections, Oncologic Disease
Biodistribution and Pathophysiology Study of 18F-Fluorodeoxysorbitol (18F-FDS) in Diseased Patients
In this study, the investigators will assess the hypothesis that this new positron emission tomography (PET) radiopharmaceutical, 18F-Fluorodeoxysorbitol (18F-FDS), will specifically localize at sites of Gram-negative bacterial…
- Conditions
- Enterobacterial Infections, Oncologic Disease, Inflammatory Disease, Invasive Fungal Infections
- Trial name
- NCT05611892
- Testing
- 18F-FDS PET/CT
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Johns Hopkins University
Invasive Fungal Disease, Mold Invasive Fungal Infection: Aspergillus, Mucorales, Fusarium, Scedosporium
Immunomonitoring of Mold Invasive Infections
Mold invasive infections are associated with an important mortality despite optimization of the antifungal treatment. In a few case reports, immune checkpoints inhibitors, initially developed for neoplastic diseases, have shown a…
- Trial name
- IMMUNOFIL (NCT06285188)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Invasive Fungal Infections
Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds
This is a Phase 2, multicenter study to evaluate APX001 for the treatment of invasive fungal infections caused by Aspergillus spp. or rare molds (eg, Scedosporium spp., Fusarium spp., and Mucorales fungi).
- Trial name
- AEGIS (NCT04240886)
- Testing
- fosmanogepix
- Where
- 15 sites in United States, Belgium and 2 more
- Volunteers
- 21 people
- Sponsor
- Basilea Pharmaceutica
Invasive Fungal Disease, Chronic Disseminated Candidiasis
Hepatosplenic CANdidiasis : PETscan and Immune Response Analysis
The purpose of this study is to determine whether F18 fluorodeoxyglucose (18F-FDG) positron-emission tomography scan (PET scan) is useful for the therapy strategy of hepatosplenic candidiasis.
- Conditions
- Invasive Fungal Disease, Chronic Disseminated Candidiasis, Hematological Malignancies, Hematopoietic Stem Cell Transplantation
- Trial name
- CANHPARI (NCT01916057)
- Testing
- 18F-FDG PET Scan
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Invasive Fungal Infections
Siderophore-labelled Positron Emission Tomography for Correlating Invasive Fungal InfeCtions
This trial will demonstrate localised uptake of a radiolabelled fungal component (siderophore) in areas of known specific invasive fungal (Aspergillus) infection.
- Trial name
- SPECIFIC (NCT06105411)
- Testing
- 68Ga-labelled TAFC PET/CT scan
- Where
- Australia
- Volunteers
- 10 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Invasive Fungal Disease
Liposomal Amphotericin B and Isavuconazole/Posaconazole in Br-IFD（ Breakthrough Invasive Fungal Disease） in Patients With Malignant Hematological Diseases
This is a prospective, open label, controlled, single center real-world observational study. Adult (aged ≥ 18 years) patients with hematological malignancies develop breakthrough invasive fungal disease after receiving ≥ 7 days…
- Trial name
- NCT07135778
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Invasive Fungal Infections, Hyperbaric Oxygen Therapy
Hyperbaric Oxygen Therapy Used on Severely Injured Healthy Individuals With Fungal Infections
The goal of this observational study is to learn about the effects of Hyperbaric Oxygen Therapy on healthy individual who suffer from invasive fungal infection caused by severe trauma, who do not respond to conventional…
- Trial name
- NCT07120581
- Testing
- Hyperbaric Oxygen Therapy
- Where
- Israel
- Volunteers
- 7 people
- Sponsor
- Assaf-Harofeh Medical Center
Invasive Fungal Infections
Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal Infections
The EAP is intended to provide a treatment option for patients with proven or probable serious or life-threatening invasive fungal infection (in accordance with the EORTC-MSGERC criteria) who have exhausted their treatment…
- Trial name
- NCT06433128
- Testing
- Fosmanogepix solution for infusion, Fosmanogepix 400 mg tablets
- Sponsor
- Basilea Pharmaceutica
Antifungal Agents, Invasive Fungal Infections
Anti-fungal Strategies in Acute-on-Chronic Liver Failure Patients
Early treatment of invasive fungal infections (IFI) may prevent undue mortality in acute on chronic liver failure (ACLF) patients.
- Conditions
- Antifungal Agents, Invasive Fungal Infections, Mycoses, Acute-On-Chronic Liver Failure
- Trial name
- NCT04157465
- Testing
- Treatment strategy trial
- Where
- India
- Volunteers
- 216 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Invasive Fungal Infections, Prophylaxis
L-AmB_ Retrospective mUlticenter Study on Mycosis prOphylaxis
Invasive fungal disease (IFD) still represents an important cause of morbidity and mortality in immunocompromised patients, particularly in patients undergoing antineoplastic chemotherapy or allogeneic hemopoietic stem cell…
- Conditions
- Invasive Fungal Infections, Prophylaxis, Invasive Fungal Disease
- Trial name
- L-AmB_RUSCO (NCT06640296)
- Testing
- Liposomal Amphotericin B (LAmB)
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- Istituto Giannina Gaslini
Leukemia, Leukemia, Myeloid
Breath Analysis for the Detection of Invasive Fungal Infections
Patients with leukemia and concomitant neutropenia are at high risk of developing invasive fungal infections (IFI) that are associated with high morbidity and mortality.
- Conditions
- Leukemia, Leukemia, Myeloid, Leukemia, Lymphoblastic, Neutropenia
- Trial name
- REDEFINE (NCT06537726)
- Testing
- Secondary electrospray ionization high-resolution mass spectrometry (SESI-HRMS)
- Where
- Switzerland
- Volunteers
- 130 people
- Sponsor
- University of Zurich
Invasive Fungal Infections
Rezafungin Paediatric PK Study in Paediatric Subjects From Birth to <18 Years of Age
This study aimed to learn what levels of rezafungin were in the blood after dosing and how safe it was, in children and adolescents below 18 years old who were already receiving treatment for a fungal infection, a suspected…
- Trial name
- NCT05534529
- Testing
- Rezafungin Acetate
- Where
- 10 sites in Germany, Spain and 1 more
- Volunteers
- 32 people
- Sponsor
- Mundipharma Research Limited
Invasive Fungal Infection
Study to Assess the Safety and Efficacy of Intravenous BSG005 in Patients With Invasive Fungal Infection
This study is an open-label, Phase 1b, dose-escalation/finding study to assess the safety and efficacy of intravenous BSG005 in patients with uncomplicated invasive fungal infections (IFI).
- Trial name
- NCT06678113
- Testing
- BSG005
- Where
- India
- Volunteers
- 15 people
- Sponsor
- Biosergen AS
Posaconazole, Pharmacokinetics
Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants
The purpose of the study is to investigate the pharmacokinetics of oral dosage of Posaconazole which is routinely administered as a standard care prophylaxis for patients undergoing cancer treatments.
- Conditions
- Posaconazole, Pharmacokinetics, Invasive Candidiases, Invasive Aspergillosis
- Trial name
- POPULAR (NCT03717623)
- Testing
- Posaconazole pharmacokinetics
- Where
- Australia
- Volunteers
- 100 people
- Sponsor
- Melbourne Health